所有图片(1)
About This Item
线性分子式:
(CH3)2S · BH3
CAS号:
分子量:
75.97
Beilstein:
3663489
MDL编号:
UNSPSC代码:
12352112
PubChem化学物质编号:
推荐产品
表单
liquid
反应适用性
reagent type: reductant
浓度
1.0 M in methylene chloride
密度
1.287 g/mL at 25 °C
储存温度
2-8°C
SMILES字符串
B.CSC
InChI
1S/C2H6S.BH3/c1-3-2;/h1-2H3;1H3
InChI key
RMHDLBZYPISZOI-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
应用
用作区域选择性还原剂的反应物
涉及的反应物：
涉及的反应物：
- 硼氢化/氧化
警示用语：
Danger
危险分类
Acute Tox. 4 Oral - Carc. 2 - Eye Dam. 1 - Flam. Liq. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3 - Water-react 2
靶器官
Central nervous system
WGK
WGK 2
个人防护装备
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Isidoro González-Álvaro et al.
Rheumatology (Oxford, England), 54(7), 1200-1209 (2014-12-21)
The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Recommendations were established via consensus by a panel of experts in
Santiago Palacio et al.
International journal of stroke : official journal of the International Stroke Society, 10(5), 686-691 (2013-05-23)
It remains controversial whether dual antiplatelet therapy reduces stroke more than aspirin alone. We aimed to assess the effects of adding clopidogrel to aspirin on the occurrence of stroke and major haemorrhage in patients with vascular disease. Meta-analysis of published
Elin S Gray et al.
Oncotarget, 6(39), 42008-42018 (2015-11-03)
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors
Jeong Won Jang et al.
Hepatology (Baltimore, Md.), 61(6), 1809-1820 (2015-01-30)
The effect of viral suppression on long-term disease outcome after decompensation in patients with hepatitis B virus (HBV)-related cirrhosis has not been established. The aim of this study was to determine the long-term effect of antiviral therapy (AVT) in patients
Marieke M ter Wee et al.
Annals of the rheumatic diseases, 74(6), 1233-1240 (2014-05-14)
Recently, we documented the likely non-inferiority of Combinatietherapie Bij Reumatoïde Artritis (COBRA)-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day) compared with the original COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持